Next Article in Journal
Platelet-Rich Plasma (PRP) Rinses for the Treatment of Non-Responding Oral Lichen Planus: A Case Report
Next Article in Special Issue
Immune Landscape of Breast Cancers
Previous Article in Journal
The Role of Photodynamic Therapy in the Treatment of Vulvar Intraepithelial Neoplasia
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessReview
Biomedicines 2018, 6(1), 14; https://doi.org/10.3390/biomedicines6010014

Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic

NanoString, Inc., Seattle, WA 98109, USA
*
Author to whom correspondence should be addressed.
Received: 12 January 2018 / Revised: 26 January 2018 / Accepted: 29 January 2018 / Published: 2 February 2018
(This article belongs to the Special Issue Dissecting the Immunological Landscape of Human Malignancies)
Full-Text   |   PDF [605 KB, uploaded 7 February 2018]   |  

Abstract

The recent successes in the use of immunotherapy to treat cancer have led to a multiplicity of new compounds in development. Novel clinical-grade biomarkers are needed to guide the choice of these agents to obtain the maximal likelihood of patient benefit. Predictive biomarkers for immunotherapy differ from the traditional biomarkers used for targeted therapies: the complexity of the immune response and tumour biology requires a more holistic approach than the use of a single analyte biomarker. This paper reviews novel biomarker approaches for the effective development of immune-oncology therapies, highlighting the promise of the advances in next-generation gene expression profiling that allow biologic information to be efficiently organized and interpreted for a maximum predictive value at the individual patient level. View Full-Text
Keywords: biomarker; immunotherapy; immuno-oncology; PanCancer IO360; gene expression profiling; gene expression signature; NanoString biomarker; immunotherapy; immuno-oncology; PanCancer IO360; gene expression profiling; gene expression signature; NanoString
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Cesano, A.; Warren, S. Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic. Biomedicines 2018, 6, 14.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top